Ovarian cancer is the 7th most common cancer in women and the 18th most common cancer overall worldwide. This cancer is usually fatal, and is the 8th most common cause of cancer death in females worldwide (14th overall).
EMMPRIN (CD147) is a marker that has been proposed to be implicated in tumorogensis, invasion and metastasis of many malignant tumors.
The aim of this study was to evaluate the expression of EMMPRIN (CD147) in cases of benign, borderline, and malignant epithelial ovarian tumors and to compare these results with other clinicopathological data trying to assess the role of CD147 in epithelial ovarian cancers. Statistical analysis was made for all grades.
This retrospective study was carried on 73 cases of epithelial ovarian tumors classified as 20 cases of benign cystadenomas, 8 cases of borderline tumors, and 45 cases of epithelial ovarian carcinomas.
Histopathological examination of the cases revealed statistically significant positive correlations between grade of epithelial ovarian carcinoma and age of the patient, primary tumor size, lymph node metastasis, distant metastasis, and TNM stage. In addition, there was a statistically significant positive correlation between the histological type of the epithelial ovarian carcinoma and the TNM stage.
EMMPRIN (CD147) immunostaining was performed for each case and was correlated with other clinicopathological parameters. EMMPRIN was detected as membranous or/and cytoplasmic brown staining and was evaluated by the percentage of positive cells. Then this percentage was scored as 0 (negative), +1 (1-50%), +2 (51-74%), and +3 (≥75 %).
There was a high statistical significant positive correlation between CD147 expression and the tumor behavior (P-value |
